Fore (Drug Discovery) Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Employees
  • 38

Employees
  • Latest Deal Type
  • Series C

  • Investors
  • 15

Fore (Drug Discovery) General Information

Description

Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and genomically defined cancer patients. The company's clinical-stage drug development aids to recapitulate naturally occurring mutations in vitro and tests their effect on signaling pathway activity and their response to different compounds, enabling biopharma companies to get support in identifying new target mutations and expanded subgroups of cancer patients to respond to existing therapies.

Contact Information

Website
www.fore.bio
Formerly Known As
NovellusDx
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 3675 Market Street
  • Philadelphia, PA 19104
  • United States
+1 (215) 000-0000

Fore (Drug Discovery) Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fore (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series C) 01-Feb-2022 000.00 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series C) 21-Sep-2020 0000 000.00 Completed Clinical Trials - Phase 1
6. Merger/Acquisition 17-Dec-2018 Cancelled Clinical Trials - Phase 1
5. Later Stage VC 30-Apr-2018 000 000.00 00.00 Completed Clinical Trials - Phase 1
4. Grant 31-Jan-2017 00000 000.00 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series A) 22-Jun-2016 000.00 000.00 000.00 Completed Clinical Trials - Phase 1
2. Seed Round 01-Jan-2014 $1.14M $5.14M Completed Clinical Trials - Phase 1
1. Seed Round 01-Jul-2013 $4M $4M Completed Clinical Trials - Phase 1
To view Fore (Drug Discovery)’s complete valuation and funding history, request access »

Fore (Drug Discovery) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and genomica
Drug Discovery
Philadelphia, PA
38 As of 2022
000.00
00000000000 000.00

000000

minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Dui
0000 000000000
Roseville, MN
00 As of 0000
000.00
000000&0 000.00

00 000

dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore ma
0000 000000000
Copenhagen, Denmark
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Fore (Drug Discovery) Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biothera Pharmaceuticals Formerly VC-backed Roseville, MN 00 000.00 000000&0 000.00
00 0000000 Formerly VC-backed Copenhagen, Denmark 00 00000 00000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Mountain View, CA 00 000.00 000000000 - 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 52 competitors. Get the full list »

Fore (Drug Discovery) Patents

Fore (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2970897-A1 Systems, devices, kits and methods for seeding cells or sets of molecules in an array on a substrate Abandoned 15-Dec-2014 000000000
US-20170362557-A1 Systems, devices, kits and methods for seeding cells or sets of molecules in an array on a substrate Abandoned 15-Dec-2014 000000000
EP-3234103-A4 Systems, devices, kits and methods for indirect transfection of multiple sets of nucleic-acids and transfer of molecules Withdrawn 15-Dec-2014 00000000000 0
US-20170362588-A1 Systems, devices, kits and methods for indirect transfection of multiple sets of nucleic-acids and transfer of molecules Abandoned 15-Dec-2014 00000000000
CA-2970900-A1 Systems, devices, kits and methods for indirect transfection of multiple sets of nucleic-acids and transfer of molecules Abandoned 15-Dec-2014 C12N15/1082
To view Fore (Drug Discovery)’s complete patent history, request access »

Fore (Drug Discovery) Executive Team (12)

Name Title Board Seat Contact Info
Michael Vidne Ph.D Chief Business & Strategy Officer
Gabi Tarcic Ph.D Chief Technology Officer
Yaron Shimon Vice President of Finance and Operation
Stacie Shepherd MD Chief Medical Officer
Matthew Ros Chief Executive Officer & Board Member
You’re viewing 5 of 12 executive team members. Get the full list »

Fore (Drug Discovery) Board Members (17)

Name Representing Role Since
Asaf Shinar Pontifax Venture Capital Board Member 000 0000
Chandra Leo MD HBM Partners Board Member 000 0000
Dieter Weinand Self Chairman 000 0000
Erez Chimovits OrbiMed Board Member 000 0000
Heiner Dreismann Fore (Drug Discovery) Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Fore (Drug Discovery) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Fore (Drug Discovery) Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
SR One Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »